- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01664078
A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION) (INSPIRATION)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the US, abdominal aortic aneurysms (AAA) are found in 4-8% of older men and 0.5-1.5% of older women, resulting in 30,000-40,000 elective procedures and 1,400 peri-operative deaths. The most significant complication of AAA is an aneurysm sac rupture from which more than 15,000 patients die annually and is the 15th leading cause of death in elderly between 60 to 85 years of age . In Japan, it is estimated that approximately 14,000 endovascular aneurysm repair (EVAR) and open surgical repair cases were performed in the year 2010 .
Abdominal aortic aneurysms can be treated three ways: (1) Medical management; (2) Open surgical repair; and (3) Endovascular aneurysm repair (EVAR). EVAR has emerged as an alternative treatment of AAA for most patients. It is less invasive than open repair and carries lower rates of early mortality and morbidity . It has also extended treatment options to patients who cannot undergo conventional surgical procedures due to a high operative risk. As EVAR technology evolves, it allows treatment of AAA with increasing complexity of the aortic neck and access vessels.
The InCraft® AAA Stent Graft System is designed for endovascular repair of infrarenal AAAs with complex aortic anatomies. This stent-graft system utilizes nitinol stent and polyester graft technology in an ultra-low profile delivery system, which assists the physician in deploying the device in a controlled, consistent, and precise manner within the aortic neck and iliac arteries. By isolating the aneurysmal sac, the system provides an alternative blood flow path to relieve pressure on the arterial vessel walls and minimize aneurysm growth and the potential for aneurysm sac rupture.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Expanded Access
Contacts and Locations
Study Locations
-
-
Tokyo
-
Minato-ku, Tokyo, Japan, 105-8461
- Takao Ohki, MD
-
-
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15217
- Michel S. Makaroun, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject must meet ALL of the following inclusion criteria to be enrolled in the study:
- Male or Female age 20 years or older;
- Proximal aortic neck is 17-31mm in diameter;
- Supra-renal aorta, at 20mm above the anticipated landing location, is smaller than the nominal diameter of the aortic bifurcate prosthesis to be used;
- Infra-renal aortic neck is ≥10mm in length with supra-renal and infra-renal angulations ≤60°;
Subject has at least one of the following:
- AAA size > 5.0 cm;
- Increase of the AAA diameter of > 0.5 cm over the last 6 months;
- Abdominal treatment length (lowest renal artery origin to the aortic bifurcation) ≥ 9.4cm;
- Aortic bifurcation >18mm in diameter;
- Iliac landing zone ≥15mm in length;
- Iliac landing zone 7-22mm in diameter;
- Minimum access vessel size of ≥ 5mm;
- Minimum overall AAA treatment length (from lowest renal artery to distal landing zone) of 128 mm;
- Women of child bearing potential must be non-pregnant, non-lactating, and not planning to become pregnant during the course of the trial; and have a negative urine or serum pregnancy test within 7 days prior to index procedure;
- Provide written informed consent and as applicable written HIPAA authorization (For US sites only) prior to initiation of study procedures;
- Willing to comply with the specified follow-up evaluation schedule.
Exclusion Criteria:
Subjects will be excluded if ANY of the following exclusion criteria apply:
- Vascular anatomy in which the placement of the stent-graft will cause occlusion of both internal iliac arteries or necessitates surgical occlusion of both internal iliac arteries;
Subject has one of the following:
- Aneurysm sac rupture or leaking abdominal aortic aneurysm;
- Mycotic, dissecting, or inflammatory abdominal aortic aneurysm;
- Clinically significant acute vascular injury due to trauma;
- Significant aortic or iliac mural thrombus, plaque or calcification that would compromise fixation and seal of the device;
- A conical aortic neck defined as >3mm distal increase over a 10mm length in the planned seal zone;
- Thoracic aortic aneurysm ≥45mm;
- Any aortic dissection;
- Morbid obesity (BMI >40.0 kg.m2) or other clinical conditions that limit required imaging studies or visualization of the aorta;
- Renal insufficiency (Creatinine > 2.0mg/dL) or subject on renal dialysis;
- Known allergy or intolerance to nickel titanium (nitinol) , Polyethylene terephthalate (PET), or polytetrafluoroethylene (PTFE);
- Known contraindication to undergoing angiography or anticoagulation (e.g. contrast allergies which cannot be treated);
- Connective tissue disorder (such as Marfan's Syndrome or Ehlers-Danlos Syndrome);
- Coagulopathy, bleeding disorder, or other hypercoagulable state;
- Organ transplant recipient or subject requiring systemic immunosuppressant therapy;
- Cerebral vascular accident (CVA), MI, or intracranial bleeding within 3 months prior to the procedure;
- Active infection or chronic systemic illness at the time of index procedure that may interfere with the study objectives;
- Major surgical procedure within 1 month prior to the index procedure or pre-planned within 1 month afterwards;
- Co-existing condition with a life expectancy of less than 2 years at time of procedure;
- Current or planned participation in any other investigational drug or medical device clinical study that has not completed primary endpoint(s) evaluation;
- Existing AAA surgical graft and/or a AAA stent-graft system;
- Other medical, social, or psychological issues that in the opinion of the investigator preclude the subjects from receiving this treatment, and the procedures and evaluations pre- and posttreatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: InCraft® - AAA stent graft system
Intervention: Endovascular AAA repair using the InCraft device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Incidence of MAE (Major Adverse Events) Based Upon a Composite MAE Rate
Time Frame: 30 days post-procedure
|
defined as a composite of:
|
30 days post-procedure
|
Number of Participants With Successful Aneurysm Treatment
Time Frame: Up to 1 year post-procedure
|
Successful aneurysm treatment which is a composite endpoint of the following:
|
Up to 1 year post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure-related Complications
Time Frame: Through 1 month, 180-days, 360-days and annually to 5-years post-procedure
|
Adverse events that are a result of the procedure itself.
|
Through 1 month, 180-days, 360-days and annually to 5-years post-procedure
|
Aneurysm-related Mortality
Time Frame: At 30-days, 180-days, 360-days and annually to 5-years post-procedure
|
At 30-days, 180-days, 360-days and annually to 5-years post-procedure
|
|
Incidence of Secondary Interventions
Time Frame: through 5 years
|
The incidence of secondary interventions within 1 year post-procedure, needed to prevent the occurrence of a significant event.
Significant event being defined as: aneurysm enlargement (growth > 5 mm), stent graft migration (> 10mm) compared to the one month size, endoleak type I / III, graft occlusion, sac rupture.
|
through 5 years
|
Major Adverse Events (MAEs) and Individual Components of the MAEs
Time Frame: At 180-days, 360-days and annually to 5-years post-procedure
|
At 180-days, 360-days and annually to 5-years post-procedure
|
|
Device-related Events
Time Frame: At 1 month, 6 months, 1 year and annually to 5-years post-procedure
|
Endoleak(s), Aneurysm sac rupture, Fracture(s, Delivery System Malfunction, Device Malfunction, Stent Graft Migration - evidence of proximal or distal movement of the stent graft >10mm relative to fixed anatomic landmarks compared with 1 month, Graft Occlusion (including unilateral or bilateral limb occlusion, Conversion to open surgery, and Aneurysm Enlargement - defined as an increase in maximum aneurysm cross sectional diameter > 5mm compared to the 1-month measurement.
|
At 1 month, 6 months, 1 year and annually to 5-years post-procedure
|
Technical Success Confirmed by CT or Other Imaging Modality
Time Frame: At 30-days
|
The study evaluated technical success at 30-days as one of the secondary effectiveness endpoints.
The definition of technical success is defined as patency of the endovascular graft, with the absence of Type I or III endoleaks or aneurysm sac rupture, up to 30-days post-procedure completion as confirmed by CT or other imaging modality.
|
At 30-days
|
Length of Hospital Stay (Days) Post Index Procedure
Time Frame: up to 17 days
|
up to 17 days
|
|
Length of Intensive Care Unit (ICU) Stay (Hours) Post Index Procedure
Time Frame: up to 48 hours
|
up to 48 hours
|
|
Length of the Index Procedure (Minutes)
Time Frame: 1 day
|
1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Post-Operatively
Time Frame: Baseline, 1 month, 6 months and 1 year post-procedure
|
Outcome measured by the SF36v2 Health Status Survey where all items are scored so that a high score defines a more favorable health state.
Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
|
Baseline, 1 month, 6 months and 1 year post-procedure
|
Physical Functioning Post-operatively
Time Frame: Screening, 1 month, 6 months and 1 year post-procedure
|
Physical Functioning (PF) Outcome measured by the SF36v2 Health Status Survey where all items are scored so that a high score defines a more favorable health state.
Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
|
Screening, 1 month, 6 months and 1 year post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michel S Makaroun, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P11-4601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aortic Aneurysm
-
Assistance Publique - Hôpitaux de ParisUnknownSmall Abdominal Aortic Aneurysm | Abdominal Aortic Aneurysm,France
-
Karolinska University HospitalEnrolling by invitationAneurysm | Aortic Aneurysm | Abdominal Aortic Aneurysm, Ruptured | Aneurysm Abdominal | Abdominal Aortic Aneurysm Without RuptureSweden
-
EndologixActive, not recruiting1 Paravisceral Abdominal Aortic Aneurysm | 2 Juxtarenal Abdominal Aortic Aneurysm | 3 Pararenal Abdominal Aortic Aneurysm | 4 Complex Abdominal Aortic AneurysmsUnited States
-
Medtronic CardiovascularCompletedAbdominal Aortic Aneurysms (AAA)United States
-
Vascutek Ltd.TerminatedAbdominal Aortic Aneurysms (AAA)United Kingdom, Netherlands, Switzerland, Spain, Germany, Belgium, Sweden, Canada, France, Italy, Austria, Monaco
-
Washington University School of MedicineRecruitingAbdominal Aortic Aneurysm (AAA) | No Abdominal Aortic Aneurysm (Non-AAA)United States
-
University of California, San DiegoRecruitingJuxtarenal Aortic Aneurysm | Thoracoabdominal Aortic Aneurysm | Pararenal Aortic Aneurysm | Complex Abdominal Aortic AneurysmUnited States
-
Timothy Chuter, MDRecruitingThoracoabdominal Aortic Aneurysm | Paravisceral Abdominal Aortic AneurysmUnited States
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingJuxtarenal Abdominal Aortic AneurysmChina
-
Medtronic CardiovascularRecruitingAAA - Abdominal Aortic AneurysmSpain, Germany, Portugal, Switzerland, Austria, France, Greece, Ireland, Italy, Netherlands, Russian Federation, Slovakia, Sweden, United Kingdom
Clinical Trials on Endovascular AAA repair with InCraft®
-
Cordis CorporationNo longer available
-
Medtronic CardiovascularCompletedAbdominal Aortic Aneurysms (AAA)United States
-
Marc van SambeekActive, not recruitingAbdominal Aortic Aneurysm (AAA)Netherlands, Italy, United Kingdom, Spain, France
-
Medtronic CardiovascularTerminated
-
Medtronic CardiovascularTerminatedAbdominal Aortic Aneurysm | AAANetherlands, Belgium, Denmark, Sweden, Austria
-
Cook Group IncorporatedApproved for marketingAbdominal Aortic Aneurysms | Aorto-iliac Aneurysms | Juxtarenal AneurysmsUnited States
-
Cook Research IncorporatedCompletedAbdominal Aortic Aneurysm (AAA) | Aorto-iliac Aneurysm | Juxtarenal AneurysmUnited States
-
Cook Research IncorporatedCompletedAortic Aneurysm, AbdominalUnited States
-
Cook Group IncorporatedTerminatedAbdominal Aortic Aneurysm | Aorto-iliac AneurysmNetherlands, United Kingdom, Germany, Norway, Austria, Ireland, Italy
-
St. Olavs HospitalCompleted